Replimune Group, Inc. (REPL) on Thursday announced positive results from the primary analysis of the IGNYTE clinical trial involving RP1 and nivolumab for patients with anti-PD1 failed melanoma. Following this news, the stock is up 25%.
The trial's anti-PD1 failed melanoma group included 140 participants, and the primary data revealed a 33.6% overall response rate at the 12-month mark.
The combination of RP1 and nivolumab remains well-tolerated, with predominantly Grade 1-2 constitutional-type side effects being observed.
Furthermore, the company intends to submit a Biologics license application in the latter half of 2024 and is gearing up for a commercial launch next year.
Currently, REPL's stock is trading at $6.99, up 25.68% on Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.